Globus Medical, headquartered in Audubon, Pennsylvania, is advancing in musculoskeletal care with innovative solutions to improve patients' lives. The company's ExcelsiusGPS robotic navigation system has gained popularity in spine surgeries, contributing to a 27% year-over-year growth in the enabling technology segment, reaching $32 million in Q1—the highest since its launch. Additionally, Globus expanded its portfolio by acquiring Pulse, a spine surgery platform, through a $3.1 billion purchase of Nuvasive. This acquisition positions Globus to enter the joint reconstruction market, with a new robot expected to revolutionize the field.
The upcoming reconstruction robot, pending FDA approval, integrates imaging, navigation, and robotics expertise, differentiating it from competitors in the commoditized hip and knee implant market. The early clearance allows Globus to enter the global hip and knee market sooner than anticipated, offering new growth opportunities. The company also plans to introduce a cementless knee later this year, furthering its commitment to enhancing patient care. A Globus spokesperson confirmed the clearance, and although initial sales contributions in 2024 are expected to be modest, the company aims to increase its market share in the US reconstruction market steadily. These developments underscore Globus Medical's dedication to innovation and patient-centered care.
